Boston Scientific (BSX) Asset Writedowns and Impairment (2010 - 2025)

Boston Scientific (BSX) has 7 years of Asset Writedowns and Impairment data on file, last reported at $51.0 million in Q4 2025.

• For the quarter ending Q4 2025, Asset Writedowns and Impairment fell 53.64% year-over-year to $51.0 million; the trailing twelve-month figure through Dec 2025 stood at $188.0 million (up 135.0% YoY), and the FY2025 full-year result was $124.0 million, down 67.88% from the prior year.
• Asset Writedowns and Impairment climbed to $51.0 million in Q4 2025, from $27.0 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $197.0 million in Q4 2021 to a low of -$31.0 million in Q4 2023.
• A 5-year average of $72.6 million and a median of $51.0 million in 2025 frame the typical range for Asset Writedowns and Impairment.
• Across the five-year window, Asset Writedowns and Impairment plunged 99.2% in 2023 and surged 454.84% in 2024, its largest moves.
• Tracing BSX's Asset Writedowns and Impairment over 5 years: stood at $197.0 million in 2021, then plunged by 36.55% to $125.0 million in 2022, then slumped by 124.8% to -$31.0 million in 2023, then surged by 454.84% to $110.0 million in 2024, then slumped by 53.64% to $51.0 million in 2025.
• Business Quant data shows BSX's Asset Writedowns and Impairment at $51.0 million in Q4 2025, $27.0 million in Q3 2025, and $110.0 million in Q4 2024.